Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SNS-101 by Sensei Biotherapeutics for Solid Tumor: Likelihood of Approval
SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
SNS-101 by Sensei Biotherapeutics for Colorectal Cancer: Likelihood of Approval
SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
SNS-101 by Sensei Biotherapeutics for Melanoma: Likelihood of Approval
SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Melanoma. According to GlobalData, Phase II...
SNS-101 by Sensei Biotherapeutics for Head And Neck Cancer: Likelihood of Approval
SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Head And Neck Cancer. According to...
SNS-101 by Sensei Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of Sensei Biotherapeutics's SNS-101?
SNS-101 is a monoclonal antibody commercialized by Sensei Biotherapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer....